Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Danegaptide for primary percutaneous coronary intervention in acute myocardial infarction patients: a phase 2 randomised clinical trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Clinical implications of electrocardiographic bundle branch block in primary care

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prevalence of heart failure and other risk factors among first-degree relatives of women with peripartum cardiomyopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Different defibrillation strategies in survivors after out-of-hospital cardiac arrest

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Syncope and orthostatic hypotension: early markers of cardiac disease in the general population

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Heritability of resting heart rate and association with mortality in middle-aged and elderly twins

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Association between Type D personality and outcomes in patients with non-ischemic heart failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A More COMPLETE Picture of Revascularization in STEMI

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVES: Reperfusion immediately after reopening of the infarct-related artery in ST-segment elevation myocardial infarction (STEMI) may cause myocardial damage in addition to the ischaemic insult (reperfusion injury). The gap junction modulating peptide danegaptide has in animal models reduced this injury. We evaluated the effect of danegaptide on myocardial salvage in patients with STEMI.

METHODS: In addition to primary percutaneous coronary intervention in STEMI patients with thrombolysis in myocardial infarction flow 0-1, single vessel disease and ischaemia time less than 6 hours, we tested, in a clinical proof-of-concept study, the therapeutic potential of danegaptide at two-dose levels. Primary outcome was myocardial salvage evaluated by cardiac MRI after 3 months.

RESULTS: From November 2013 to August 2015, a total of 585 patients were randomly enrolled in the trial. Imaging criteria were fulfilled for 79 (high dose), 80 (low dose) and 84 (placebo) patients eligible for the per-protocol analysis. Danegaptide did not affect the myocardial salvage index (danegaptide high (63.9±14.9), danegaptide low (65.6±15.6) and control (66.7±11.7), P=0.40), final infarct size (danegaptide high (19.6±11.4 g), danegaptide low (18.6±9.6 g) and control (21.4±15.0 g), P=0.88) or left ventricular ejection fraction (danegaptide high (53.9%±9.5%), danegaptide low (52.7%±10.3%) and control (52.1%±10.9%), P=0.64). There was no difference between groups with regard to clinical outcome.

CONCLUSIONS: Administration of danegaptide to patients with STEMI did not improve myocardial salvage.

TRIAL REGISTRATION NUMBER: NCT01977755; Pre-results.

Original languageEnglish
JournalHeart (British Cardiac Society)
Volume104
Issue number19
Pages (from-to)1593-1599
Number of pages7
ISSN1355-6037
DOIs
Publication statusPublished - Oct 2018

ID: 56239750